<DOC>
	<DOC>NCT01482221</DOC>
	<brief_summary>The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the NMDA class of glutamate receptors.</brief_summary>
	<brief_title>A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Provision of signed and dated informed consent before initiation of any studyrelated procedures. Male or female patients aged 18 to 70 years, inclusive. The patient must have a clinical diagnosis of major depressive disorder with a lifetime history of inadequate response to at least 3 antidepressants. Women of childbearing potential must have a negative serum pregnancy test and confirmed use of a highly effective form of birth control before enrollment for a minimum of 3 months before study start. Outpatient status at screening and randomization visits. Patients with a history of diagnosed bipolar disorder or schizophrenia or schizoaffective disorder or currently exhibiting psychotic features associated with their depression; dementia or suspicion thereof. Patients who have had a suicide attempt within the last 6 months. Electroconvulsive therapy (ECT), vagal nerve stimulation (VNS) or transcranial magnetic stimulation (TMS) or previous treatment with ketamine infusion within the 6 months prior to screening, or any history of deep brain stimulation. Patients with any history of seizure disorder (except for febrile seizures in childhood). Pregnancy or lactation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Inadequate Response to Antidepressant Therapy</keyword>
	<keyword>Channel blocker of the NMDA class of glutamate receptors</keyword>
</DOC>